Rapamycin / Sirolimus

Longevity / Immunology

Immunosuppression and longevity-positioning

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: Small molecule
Primary mechanism: mTORC1 inhibition
Primary market use: Transplant/longevity research

Pharmacology

Molecular weight (Da): 914.2
Oral bioavailability: ~14%
Half-life: ~60 h
Route tags: SubQ; Injectable; route-dependent
Evidence level: Approved
Clinical status: Approved/research longevity
Value-for-money score: 6 / 10

Reported protocol signal

No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Notes

Requires ongoing or intermittent dosing; not peptide

Sources

https://www.fda.gov/drugs